- Home
- NUS vs VSTM Comparison
NUS vs VSTM Comparison
Compare NUS & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- VSTM
- Stock Information
- Founded
- NUS 1984
- VSTM 2010
- Country
- NUS United States
- VSTM United States
- Employees
- NUS N/A
- VSTM N/A
- Industry
- NUS Other Pharmaceuticals
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- VSTM Health Care
- Exchange
- NUS Nasdaq
- VSTM Nasdaq
- Market Cap
- NUS 603.4M
- VSTM 581.6M
- IPO Year
- NUS 1996
- VSTM 2012
- Fundamental
- Price
- NUS $9.66
- VSTM $7.70
- Analyst Decision
- NUS Hold
- VSTM Strong Buy
- Analyst Count
- NUS 1
- VSTM 9
- Target Price
- NUS $7.00
- VSTM $13.38
- AVG Volume (30 Days)
- NUS 463.5K
- VSTM 2.8M
- Earning Date
- NUS 11-06-2025
- VSTM 11-04-2025
- Dividend Yield
- NUS 2.49%
- VSTM N/A
- EPS Growth
- NUS N/A
- VSTM N/A
- EPS
- NUS 2.20
- VSTM N/A
- Revenue
- NUS $1,560,391,000.00
- VSTM $13,379,000.00
- Revenue This Year
- NUS N/A
- VSTM $88.60
- Revenue Next Year
- NUS $0.98
- VSTM $416.99
- P/E Ratio
- NUS $4.37
- VSTM N/A
- Revenue Growth
- NUS N/A
- VSTM 33.79
- 52 Week Low
- NUS $5.32
- VSTM $3.46
- 52 Week High
- NUS $14.62
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- NUS 38.45
- VSTM 41.32
- Support Level
- NUS $8.90
- VSTM $7.55
- Resistance Level
- NUS $9.99
- VSTM $8.86
- Average True Range (ATR)
- NUS 0.51
- VSTM 0.60
- MACD
- NUS -0.09
- VSTM -0.07
- Stochastic Oscillator
- NUS 33.48
- VSTM 14.64
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.